Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125779 | 0.99 | SLC10A2 (0.73) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL349001 | 0.99 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL27307421 | 0.87 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL6843175 | 0.86 | SLC10A2 (0.58) | SLC10A2 | |
| Maralixibat SCHEMBL10013954 | 0.84 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL18176641 | 0.84 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL6336189 | 0.83 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564749 | 0.83 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL6336186 | 0.83 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564753 | 0.83 | SLC10A2 (1.00) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009805-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009805-A1 | Novel quaternary ammonium compounds | SLC10A1, GOT1, ACAT2 | SLC10A2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.